Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

Many factors go into deciding what type of COPD treatment may be best for you. Current medical guidelines have changed in recent years. This could mean your doctor might reevaluate your COPD ...

While COPD is not curable, it is a preventable and treatable illness. The earlier you start treatment, the better your prognosis. COPD is often asymptomatic until significant damage to the lungs has ...

Objective: This study aims to discuss the dose-response relationship between the Life's Essential 8 (LE8) score and chronic obstructive pulmonary disease (COPD). Methods: We screened data from the ...

Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the sixth leading cause of death in the United States, according to the U.S. Centers for Disease Control ...

If you’re hospitalized, your respiratory therapist may: You may get this if you have an ongoing condition such as COPD. Your therapist ... you will have to follow the guidelines for the state ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Regular use of spirometry for COPD progression tracking is important for COPD treatment ... Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research ...

2 By contrast, the 2017 American and 2024 ESC guidelines recommend prompt treatment for confirmed blood pressure above 140/90 mm Hg, irrespective of age or cardiovascular disease risk. Furthermore, ...

In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) ...

A study of adults with COPD who died between 2014 and 2018 found that 65% were prescribed at least one such drug, and 30% experienced a fall-related injury within two years of death.

A 3 mg dose of ensifentrine was linked to improved FEV1, dyspnea, and quality of life in patients with COPD, with few treatment-emergent adverse events. Ensifentrine is a promising supplementary ...